Raloxifene (Evista), a "designer estrogen" from Lilly

There's lots of interest in raloxifene (Evista), a "designer estrogen" from Lilly. It has been covered on TV, in the news, etc.

    It's being tested to prevent osteoporosis in postmenopausal women...as an alternative to using estrogen.

    Raloxifene is a "selective estrogen receptor modulator"...it has both estrogen agonist AND antagonist effects.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote